SCHEMBL4923911

SCHEMBL4923911

Cc1cccc(NC(=O)c2cccc3cccc(C(=O)NO)c23)c1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.54
HSD17B10 Q99714 5/20 0.49
LMNA P02545 3/20 0.49
HTT P42858 2/20 0.49
TSHR P16473 2/20 0.49
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
TP53 P04637 1/20 0.49
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 3/20 0.49
HPGD P15428 2/20 0.49
MAPK1 P28482 1/20 0.49
MAPT P10636 4/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
PLAU P00749 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4925909 0.88 HSD17B10 (0.58) KDRHSD17B10LMNAHTTTSHR
SCHEMBL4923931 0.84 HSD17B10 (0.54) KDRHSD17B10LMNAHTTTSHR
SCHEMBL4924169 0.81 NPC1 (0.63) HSD17B10LMNAHTTTSHRRAB9A
SCHEMBL4923998 0.80 KCNMA1 (0.60) KDRHSD17B10LMNAHTTTSHR
SCHEMBL28629544 0.78 HDAC8 (0.64) HSD17B10LMNAKDM4EMAPTSMN1; SMN2
SCHEMBL10057829 0.78 LMNA (0.64) KDRHSD17B10LMNAHTTTSHR
SCHEMBL4925011 0.77 NPC1 (0.55) KDRHSD17B10LMNAHTTRAB9A
SCHEMBL4923978 0.77 TP53 (0.51) KDRLMNAHTTRAB9ANPC1
SCHEMBL4926426 0.77 NPC1 (0.58) HSD17B10RAB9ANPC1ALDH1A1KDM4E
SCHEMBL9493594 0.77 ALDH1A1 (0.62) KDRHSD17B10HTTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2008-10-30 US disclosed
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 KDR 417/4885HSD17B10 2205/4885LMNA 4560/4885
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 KDR 428/4885HSD17B10 2336/4885LMNA 4579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.